Invitae Personalized Cancer Monitoring™ - Baseline Test
Use
The Invitae Personalized Cancer Monitoring - Baseline Test is a patient-specific assay designed to identify variants present in a patient’s tumor specimen and assess the presence or absence of that tumor-specific genetic signature in a non-invasive blood sample. It allows for minimal residual disease (MRD) detection and monitoring of anti-cancer treatment effects, including determination of quantitative changes in ctDNA abundance over time. This test is specifically designed for the detection of somatic mutations and not for identifying heritable germline mutations.
Special Instructions
The Baseline Test is required before serial ctDNA quantification via the Invitae Personalized Cancer Monitoring - Monitoring Test. Invitae cannot accept specimens from pregnant patients or those with active hematological malignancy, history of allogeneic bone marrow/stem cell transplants, or within 2 weeks after blood transfusion. Contact Invitae for specimen collection kits or more information about specimen selection.
Limitations
Relapsed or residual disease may occur with a different genomic signature than the original tumor. Low amounts of tumor-specific circulating material can result in lower signals. This methodology minimizes false negatives due to sample swaps but does not eliminate these risks. A 'Not Detected' status does not guarantee the absence of the disease nor present or future health.
Methodology
NGS (WES)
Biomarkers
Result Turnaround Time
35-42 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10mL
Minimum Volume
Not provided
Container
Streck Cell-Free DNA blood collection tube